Yarrow Bioscience (YARW) risk factors, FY2024 10-K

Risks Related to Development of Our Product Candidates

1. 01Our business is substantially dependent on the successful development of our BET inhibitor product candidates
2. 02The development of these new chemical entities carries even greater risk and a higher probability of failure. Our failure to successfully develop our product candidates will have a material adverse effect on our business and financial condition
3. 03We may encounter delays in enrolling patients and successfully completing clinical trials for our product candidates and may be delayed in, or prevented from, commencing such trials due to factors that are largely beyond our control
4. 04If we experience delays in the completion of, or if we terminate, any of our future clinical trials, our business, financial condition, operating results and prospects would be adversely affected
5. 05New chemical entities may require more time and resources for development, testing and regulatory approval
6. 06Results obtained in preclinical studies and completed clinical trials may not predict success in later clinical trials
7. 07Top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as additional data become available and are subject to audit and verification procedures that could result in material changes in the final data
8. 08We have a limited history as a clinical-stage biopharmaceutical company developing product candidates for immuno-inflammatory conditions, which may make it difficult to assess our future viability
9. 09We may spend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
10. 10We have not obtained regulatory approvals to market our product candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize these product candidates
11. 11Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates
12. 12could negatively impact us by reducing revenues or increasing expenses, and cause the product not to be commercially viable. Absence of long-term safety data may further limit the approved uses of products
13. 13We rely on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business
14. 14Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays

Risks Related to Our Financial Position and Need for Capital

1. 15We will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations
2. 16We have incurred significant losses since our inception and we anticipate that we will continue to incur significant losses for the foreseeable future, which could harm our future business prospects
3. 17SEC regulations limit the amount of funds we can raise during any 12-month period pursuant to our shelf registration statement on Form S-3
4. 18Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights
5. 19Collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates
6. 20In addition, the success of future collaboration arrangements that we may enter into will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations
7. 21We are subject to various risks and uncertainties arising out of the completed divestiture of our commercial business, any of which could materially and adversely affect our business and operations, and our stock price
8. 22We may in-license, acquire and develop additional product candidates. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates, negotiate licensing or acquisition agreements with their current owners and finance these arrangements
9. 23We may engage in strategic transactions, which could impact our liquidity, increase our expenses and present significant distractions to our management
10. 24We may decide not to continue developing any of our product candidates at any time during development or of any of our products after approval, which would reduce or eliminate our potential return on investment for those product candidates or products
11. 25Supply interruptions may disrupt the availability of our product candidates and cause delays in conducting preclinical or clinical activities
12. 26We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards
13. 27The Israeli Tax Authority may disagree with our conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits
14. 28If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully execute our strategy
15. 29We may become subject to lawsuits or investigations that could have a material adverse impact on our business, results of operations and financial condition
16. 30systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program
17. 31Our employees, independent contractors, principal investigators, consultants, vendors, CROs and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our business
18. 32Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations

Risks Related to Government Regulation

1. 33penalties, contractual damages, reputational harm, and diminished profits and future earnings. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business
2. 34In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws
3. 35Healthcare reforms by governmental authorities and related reductions in pharmaceutical pricing, reimbursement and coverage by third party payors may adversely affect our business
4. 36increase in the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs may have an adverse effect on us. It is uncertain how current and future reforms in these areas will influence the future of our business operations and financial condition
5. 37Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market, and distribute our products after clearance or approval is obtained
6. 38We and our contract manufacturers are subject to significant regulation with respect to manufacturing of our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity
7. 39We are subject to various U.S. and foreign anti-bribery and anti-corruption laws, and any violations by us of such laws could result in substantial penalties
8. 40Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
9. 41Sanctions and other trade control laws create the potential for significant liabilities, penalties and reputational harm

Risks Related to Our Intellectual Property

1. 42If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to any of our product candidates are not adequate, we may not be able to compete effectively and we otherwise may be harmed
2. 43We have in-licensed intellectual property necessary to develop our BET inhibitor product candidates, and if we fail to comply with our obligations under any of these arrangements, we could lose such intellectual property rights
3. 44Changes in U.S. or foreign patent law and practice could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
4. 45If we infringe or are alleged to infringe or otherwise violate intellectual property rights of third parties, our business could be harmed
5. 46If we are unable to secure trademark registrations, secure appropriate domain names and protect our trademarks or trade dress from infringement, our business prospects may be harmed
6. 47We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
7. 48An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing
8. 49We may not obtain intellectual property rights or otherwise be able to protect our intellectual property rights throughout the world
9. 50intellectual property rights or may infringe upon our intellectual property rights, including through means that may be difficult to prevent or detect
10. 51We may not be able to enforce covenants not to compete under applicable employment laws

Risks Related to the Ownership of Our Common Stock

1. 52The trading price of the shares of our common stock is volatile, and stockholders could incur substantial losses
2. 53Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
3. 54In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
4. 55Our directors and executive officers may be subject to litigation for a variety of claims or disputes. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
5. 56such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful
6. 57Our amended and restated certificate of incorporation and our amended and restated bylaws contain exclusive forum selection clauses, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
7. 58We are eligible to report as a “smaller reporting company,” and as a result of the reduced reporting requirements applicable to such companies, our securities may be less attractive to investors
8. 59An active public market for our common stock may not be sustained
9. 60If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
10. 61Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
11. 62We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock
12. 63If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
13. 64that we incur substantial additional professional fees and internal costs within our accounting and finance functions and that we expend significant management efforts
14. 65We incur significant costs and demands upon management as a result of being a public company
15. 66We are subject to risks related to climate change in the long term